On June 10, Tempus AI rose 5.07% in regular trading, trading at $51.12/share, with trading volume of $77.26 million. The rally was primarily driven by the continued positive momentum from the company's FDA approval of its tumor-specific xT CDx next-generation sequencing platform.

According to public filings, Tempus AI became the first laboratory to hold FDA companion diagnostic approvals for both tumor-specific and tumor-normal tissue genomic profiling. The approval is expected to generate approximately $200 in average selling price uplift starting from 2027. Additionally, the company recently launched Lens, a next-generation Agent AI platform designed for oncology drug development, and presented new multimodal oncology foundation model results at the ASCO annual meeting.

The stock had previously experienced selling pressure due to sustained insider disposals by major shareholder Eric Lefkofsky, which weighed on sentiment and contributed to a technical pullback. The current rebound is viewed as an oversold recovery following that correction, with fundamental catalysts from the FDA milestone continuing to support bullish positioning.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)